The Effect of Broccoli Sprout Extract and Probiotics for Eradication of Helicobacter Pylori

The Effect of Broccoli Sprout Extract and Probiotics on Proton Pump Inhibitor-based Triple Therapy for Eradication of Helicobacter Pylori: a Prospective Randomized Trial

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03220542

Enrollment

360

Registered

2017-07-18

Start date

2016-01-31

Completion date

2019-12-31

Last updated

2019-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection

Keywords

Helicobacter Pylori, Probiotics, Sulforaphane

Brief summary

In Korea, the first-line therapy to treat Helicobacter pylori (Hp) consists of a proton pump inhibitor (PPI) and two antibiotics for one week. But, eradication has become less successful due to low compliance and high resistance to the antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. In vitro study, we previously reported that a broccoli sprout extract containing sulforaphane may prevent lipid peroxidation in the gastric mucosa and play a cytoprotective role in Hp-induced gastritis. Also, several studies suggested that probiotics could be effective for improving Hp eradication rate or reducing adverse events. But, their effect for eradication of Hp is not yet conclusive. The aims of this prospective study is to investigate the efficacy of a broccoli sprout extract containing sulforaphane and probiotics for eradication of Hp, compared with standard triple therapy.

Interventions

DRUGProbiotics

Saccharomyces boulardii

DIETARY_SUPPLEMENTBroccoli

Broccoli sprouts extract

DRUGEsomeprazole

Esomeprazole

DRUGAmoxicillin

Amoxicillin

DRUGClarithromycin

Clarithromycin

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Helicobacter pylori infected patients * Patients with active or healing gastric/duodenal ulcers

Exclusion criteria

* prior Hp eradication therapy * previous gastric resection * previous use of proton pump inhibitors, bismuth, H2 receptor antagonist or antibiotics within 4 weeks of the study * Patients who were pregnant or lactating

Design outcomes

Primary

Measure	Time frame	Description
Helicobacter pylori eradication	5 weeks after treatment initiation	Using the urea breath test

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026